Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2016 12/02/2016 12/05/2016 12/06/2016 12/07/2016 Date
127.72(c) 127.9(c) 127.92(c) 126.4(c) 119.84 Last
2 280 047 1 594 707 1 257 926 1 246 422 950 558 Volume
-4.07% +0.14% +0.02% -1.19% -5.19% Change
More quotes
Financials ($)
Sales 2016 2 390 M
EBIT 2016 675 M
Net income 2016 435 M
Finance 2016 124 M
Yield 2016 -
Sales 2017 2 661 M
EBIT 2017 729 M
Net income 2017 491 M
Finance 2017 249 M
Yield 2017 -
P/E ratio 2016 42,76
P/E ratio 2017 37,52
EV / Sales2016 7,72x
EV / Sales2017 6,89x
Capitalization 18 568 M
More Financials
Company
Illumina, Inc. develops, manufactures and markets integrated systems for the analysis of genetic variation and function.The company provides sequencing and array-based solutions for genetic analysis in addition to selling products, it provide genotyping, NIPT and whole-genome sequencing... 
Sector
Advanced Medical Equipment & Technology
Calendar
12/07 | 02:45pmPresentation
More about the company
Surperformance© ratings of Illumina, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ILLUMINA, INC.
12/05 ILLUMINA : Amendment to Combined Synopsis/Solicitation - Illumina Sequencer Main..
12/05 ILLUMINA : Amendment to Combined Synopsis/Solicitation - Illumina NextSeq 500 Ma..
12/02 ILLUMINA : Mass Spectrometry Adopted by Clinical Laboratories Around the World
12/02 ILLUMINA : Combine Solicitation - Illumina NextSeq 500 Maintenance
12/02 ILLUMINA : Combine Solicitation - Illumina Sequencer Maintenance
12/01 ILLUMINA : Launches iHope Program to Identify Causes of Undiagnosed Genetic Dise..
11/29 ILLUMINA INC : Change in Directors or Principal Officers (form 8-K)
11/29 ILLUMINA : Contributes to ClinVar Database
11/28 ILLUMINA : to Webcast Live Presentation at the Citi Global Healthcare Conference
11/22 ILLUMINA : and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic D..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
12/05 Aixtron could revive takeover despite U.S. block
12/02 Deals scuppered by U.S. regulatory scrutiny
11/29 European spin-offs and carve-outs
11/15 EXCLUSIVE : EU regulators seen clearing $25 billion Abbott, St Jude deal
11/15 Exclusive - EU regulators seen clearing $25 billion Abbott, St Jude deal
More sector news : Advanced Medical Equipment & Technology - NEC
4-Traders Strategies on ILLUMINA, INC. 
2015We anticipate a reversal
2013End of the technical recovery
More Strategies
News from SeekingAlpha
06:48a New finance chief at Illumina
12/04 WEEK IN REVIEW : Suzhou's Innovent Biologics Announces Record $260 Million Fundi..
12/01 More Medtech Venture Cash Goes Into Series A Rounds
11/29 Illumina clinical genomics chief bids adieu
11/25 Where Will CRISPR-Cas9 Work First?
Advertisement
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | ILMN | US4523271090 | 4-Traders
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Average target price 144 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Marc A. Stapley EVP, Chief Financial & Administrative Officer
Mostafa Ronaghi Chief Technology Officer & Senior Vice President
Norman Fjeldheim Chief Information Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ILLUMINA, INC.-34.15%18 568
THERMO FISHER SCIENTIF..1.23%56 722
DANAHER CORPORATION8.49%53 524
BOSTON SCIENTIFIC CORP..12.85%28 336
PHILIPS15.41%27 639
INTUITIVE SURGICAL, IN..13.81%24 085
More Results